Plasma cell leukemia: detailed studies and response to therapy.
D000135:Acid Phosphatase / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005455:Fluorescent Antibody Technique; D005966:Glucuronidase / Q000378:metabolism; D006651:Histocytochemistry; D006801:Humans; D007122:Immunoelectrophoresis; D007128:Immunoglobulin Fragments / Q000032:analysis; D007621:Karyotyping; D007952:Leukemia, Plasma Cell / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000276:immunology / Q000473:pathology; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D010950:Plasma Cells; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D013194:Staining and Labeling; D014750:Vincristine / Q000627:therapeutic use
D007128:Immunoglobulin Fragments; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D000135:Acid Phosphatase; D005966:Glucuronidase; D008558:Melphalan; D011241:Prednisone